Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this ...

Shares of Bristol Myers Squibb Co. BMY shed 3.84% to $57.42 Thursday, on what proved to be an all-around mixed trading ...

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

Bristol-Myers Squibb (SMY) stock falls as its Q4 2024 results beat Street forecasts, but its 2025 outlook fell short of ...

(Reuters) -Bristol Myers Squibb on Thursday posted better-than-expected fourth-quarter earnings, but said its 2025 revenue ...

The drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a ...

By Michael Erman and Sriparna Roy (Reuters) -Bristol Myers Squibb on Thursday said its 2025 revenue would fall more sharply ...

Bristol Myers Squibb beat Q4 estimates with $12.34 billion revenue and $1.67 EPS. 2025 guidance lags expectations amid ...

While reporting financial results for the fourth quarter on Thursday, Bristol-Myers Squibb Co. (BMY) initiated its adjusted earnings ...

Financial discipline remained a priority, with approximately $1.1 billion of the targeted $1.5 billion in savings already realized. The company has identified an additional $2 billion in savings, with ...